Two main types of autoimmune pancreatitis (AIP) have been described: type 1, linked to IgG4-related disease, and type 2, ...

The 2025 Congress of Clinical Rheumatology West will feature expanded immunology and young investigator programs, as well as ...

A pizza shop with 30 delivery people ought to be able to deliver a lot of pizzas—if their cars don't break down on the way. Likewise, genes that produce a lot of messenger RNA (mRNA) molecules can ...

Zenas BioPharma has secured up to $300 million from Royalty Pharma in return for royalties on sales of lead autoimmune candidate obexelimab. The cash is intended to help Zenas get its star asset ...

Messenger RNA, or mRNA, vaccines entered the public consciousness when they were introduced during the COVID-19 pandemic, and both Pfizer-BioNTech and Moderna used the technology in developing their ...

The Fountain of Youth may not be all it's cracked up to be, researchers say. A genetic "fountain of youth" actually might increase seniors' risk of developing autoimmune diseases like rheumatoid ...

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing ...

Vor Bio's stock rises after RemeGen’s Phase 3 trial of telitacicept meets the primary endpoint. Telitacicept showed safety and reduced disease activity in Sjögren's patients. Up Next: Wall Street ...

Primary immunodeficiency (PI) not only increases your risk of frequent and serious infections, but can also make you more likely to develop autoimmune diseases — conditions where the immune system ...